|drug3442||Two dose ChAdOx1 nCoV-19/Covishield 0.5mL Wiki||1.00|
|drug717||ChAdOx1 nCoV-19 (Abs 260) + 2.2x10^10vp (qPCR) boost Wiki||1.00|
|drug718||ChAdOx1 nCoV-19 (qPCR) Wiki||1.00|
|drug3441||Two dose ChAdOx1 nCoV-19/Covishield 0.25mL & 0.5mL Wiki||1.00|
|drug716||ChAdOx1 nCoV-19 (Abs 260) Wiki||1.00|
|drug720||ChAdOx1 nCoV-19 0.5mL prime plus boost Wiki||1.00|
|drug3444||Two dose MenACWY vaccine min. 4 weeks apart Wiki||1.00|
|drug1966||MenACWY vaccine Wiki||1.00|
|drug3443||Two dose MenACWY vaccine Wiki||1.00|
|drug3138||Standard of Care Wiki||0.16|
There is one clinical trial.
Since the outbreak of the novel coronavirus disease in 2019 (COVID-19), an unprecedented global search for potential therapeutics and vaccines is ongoing. In this study, a combination of two drugs that have been shown to be effective against the germ that causes COVID-19 in the laboratory will be tested in patients diagnosed with moderate to severe COVID-19. One of the drugs is called nitazoxanide and the second is atazanavir/ritonavir. Nitazoxanide has been used for the treatment of diarrhea since 2004 while atazanavir/ritonavir was approved for HIV treatment in 2003. They are known to be safe in humans. In this pilot study, 98 COVID-19 patients will be recruited into two groups. The 49 patients in group 1 will receive the standard of care determined by their primary care providers while the 49 patients in group 2 will receive both the standard of care combined with the two study drugs. Patients in group 2 will receive the study drugs for 14 days and all patients will be monitored for a total of 28 days. The time it takes for the germ that causes COVID-19 to be completely removed from the body (in nasal secretions) and the time to clinical improvement will be monitored in all patients and compared between the two groups.
Description: Proportion of patients with clinical improvement, as defined by live discharge from the hospital, a decrease of at least 2 points from baseline on a 7-point ordinal scale, or both.Measure: Time to clinical improvement Time: 28 days
Description: Proportion of participants with SARS-CoV-2 polymerase chain reaction (PCR) negative result at Days 7, 10, 14 and 28Measure: Time to SARS-CoV-2 negativity Time: 28 days
Description: Temporal patterns of SARS-CoV-2 viral load quantified by RT-PCR from nasal swabs or sputum of patients receiving SOC alone versus SOC plus study drugMeasure: Difference in SARS-CoV-2 AUC Time: 28 days
Description: Time to symptoms resolution as monitored by the Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) questionnaire with some modifications for COVID-19Measure: Time to symptoms resolution Time: 28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports